- AI-screener
- Securities US
- Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
$47.03
$0.11
0.23%
24 Jun 20:00
$39.35
$63.33
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
weak bearish sentiment is waning
3day with a yield of0.17%
Share of longs and shorts
Long
100.00%Short
0.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | — | |
Support | — | |
Cash flows | — |
Momentum
Indicators for analyzing trends in the instrument. Based on them you can choose the optimal moment to open or close a position.
Return/MDD
-0.89Sentiment
BearishStart Date
06.16.2025Duration
8Yield
-3.35%Avg.Yield
-4.02%
Volatility
1.90%Max MDD
-3.76%Avg. MDD
-7.14%Min Price
RUB 46.84Max Price
RUB 48.66
Protective stop levels
S/L 5%RUB 49.27 | S/L 10%RUB 51.61 | S/L 15%RUB 53.96 | |
|---|---|---|---|
Day | 1.43% | 0.00% | 0.00% |
Week | 27.32% | 2.83% | 0.12% |
Month | 59.29% | 28.45% | 11.37% |
Technical analysis
- Trend ClassTurning down
- Trend PowerStrong trend
- PatternDivergence Channel
- EMA-20Bearish reversal2025-06-16 the price crossed down the moving average line and formed a short-term downside trend.
- EMA-50Bearish reversal2025-06-13 the price crossed down the moving average line and formed a short-term downside trend.
- EMA-100Bearish reversal2025-04-04 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- StochasticBearish WeakeningThe stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.
- RSIBearish WeakeningRSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.
- MACDBearishOscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.
- Candle pattern typeDojiIs formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | -0.11% | 1.89% | $46.71 | $47.40 | 489.69M |
| Week | -0.59% | 2.54% | $46.32 | $47.40 | 2.81B |
| Month | 0.21% | 4.72% | $46.10 | $50.76 | 10.67B |
| 3 Months | -23.17% | 2.67% | $44.00 | $61.64 | 33.27B |
| 6 Months | -18.08% | 11.02% | $44.00 | $63.33 | 56.96B |
| Year | 11.92% | 19.43% | $39.35 | $63.33 | 106.12B |
| 3 years | -40.18% | 65.07% | $39.35 | $81.44 | 317.52B |
| 5 years | -18.93% | 97.91% | $39.35 | $81.44 | 579.26B |
| All time | 9.34% | 94.26% | $16.00 | $81.44 | 583.58B |
Volatility
| BMY | By industry | |
|---|---|---|
| Yesterday | 2.64% | 0.95% |
| Week | 2.59% | 1.90% |
| Month | 8.28% | 11.44% |
| 3 Months | 16.95% | 21.81% |
| 6 Months | 23.39% | 29.79% |
| Year | 31.48% | 38.55% |
| 3 years | 43.20% | 81.89% |
| 5 years | 51.50% | 114.85% |
| All time | — | — |
Risk ratios
- Sortino
- 0.29
- Sharpe
- 0.35
- Sterling
- 0.37
- Liquidity index
- 7.29
- Alpha
- 0.00001
- Beta
- 0.30
AI Factors
Drivers of growth or decline are external factors, selected using AI, that can significantly affect the price of a company's shares in the future.
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$95.49B
Capitalization
2.04B
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
Dr. Giovanni Caforio M.D.
CEO
Website
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.